Bleomycin-mediated pulmonary toxicity evidence for a p53-mediated response

American Journal of Respiratory Cell and Molecular Biology

Volumn 22, Issue 5, 2000, Pages 543-549

  Mishra, Anil ^a   Doyle, Nicholas A ^a   Martin II, William J ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OPW 425   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0034114527     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.22.5.3851     Document Type: Article

References (52)

1. 1. Crooke, S., and W. Bradner. 1976. Bleomycin: a review. J. Med. 7:333-428.
2. 2. Giri, S. 1990. Pharmacologic perspectives in pulmonary fibrosis research. In Focus on Pulmonary Pharmacology and Toxicology. M. Hollinger, editor. CRC Press, Boca Raton, FL. 19-55.
3. 3. Aso, Y., K. Yoneda, and Y. Kikkawa. 1976. Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice. Lab. Invest. 35:558-568.
4. 4. Hakkinen, P. J., J. W. Whiteley, and H. H. Witschi. 1982. Hyperoxia, but not thoracic X-irradiation, potentiates bleomycin-and cyclophosphamide-induced lung damage in mice. Am. Rev. Respir. Dis. 126:281-285.
5. 5. Gurujeyalakshmi, G., and S. Giri. 1995. Molecular mechanisms of antifibrotic effect of interferon-γ in bleomycin-mouse model of lung fibrosis: downregulation of TGF-β and procollagen I and III gene expression. Exp. Lung Res. 21:791-808.
6. 6. Adamson, I. Y. R., and D. H. Bowden. 1979. Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Am. J. Pathol. 96:531-544.
7. 7. Chandler, D., D. Hyde, and S. Giri. 1983. Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am. J. Pathol. 112:170-177.
8. 8. Adamson, I., J. Bakowski, and D. Bowden. 1994. Mesothelial cell proliferation: a nonspecific response to lung injury associated with fibrosis. Am. J. Respir. Cell Mol. Biol. 10:253-258.
9. 9. Suzuki, H., K. Nagal, H. Yamaki, N. Takanaka, and H. Umezawa. 1968. Mechanisms of action of bleomycin: studies with the growing culture of bacterial and tumor cells. J. Antibiot. (Tokyo) 21:378-386.
10. 10. Suzuki, H., K. Nagal, H. Yamaki, N. Tanaka, and H. Umezawa. 1969. On the mechanism of action of bleomycin: scission of DNA strands in vitro and in vivo. J. Antibiot. (Tokyo) 22:446-448.
11. 11. Muller, W., and R. Zahn. 1977. Bleomycin, an antibiotic that removes thymine from double stranded DNA. Prog. Nucleic Acid Res. Mol. Biol. 20:21-57.
12. 12. Solaiman, D., E. Rao, D. Petering, R. Sealy, and W. Antholine. 1979. Chemical, biochemical and cellular properties of copper and iron bleomycins. Int. J. Radiat. Biol. 5:1519-1521.
13. 13. Moseley, P. L., M. D. Shasby, M. Brady, and G. W. Hunninghake. 1984. Lung parenchymal injury induced by bleomycin. Am. Rev. Respir. Dis. 130:1082-1086.
14. 14. Habib, M., D. Lackey R. Lantz, R. Sobonya, R. Grad, D. Earnest, and J. Bloom. 1993. Vitamin A pretreatment and bleomycin-induced rat lung injury. Res. Commun. Chem. Pathol. Pharmacol. 81:199-288.
15. 15. Iyer, S., J. Wild, M. Schiedt, D. Hyde, S. Margolin, and S. Giri. 1995. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125:779-785.
16. 16. Zhang, K., M. Gharaee-Kermani, B. McGarry, D. Remick, and S. Phan. 1997. TNF-α-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J. Immunol. 158:954-959.
17. 17. Chatterjee, A., and M. Raman. 1993. Protective effect of cysteine against X-ray-and bleomycin-induced chromosomal aberrations and cell cycle delay. Mutat. Res. 290:231-238.
18. 18. MacLoed, R., T. Buchheim, M. Kaufmann, and H. Drexler. 1996. Chromosomal breakage correlates with delayed lethality in normal and ataxia telangiectasia cell lines treated with bleomycin. Mutat. Res. 372:33-42.
19. 19. Usmani, B., J. Lunec, and G. Sherbet. 1993. DNA repair and repair fidelity in metastatic variants of the B16 murine melanoma. J. Cell. Biochem. 51:336-344.
20. 20. Harrison, J. H., Jr, D. G. Hoyt, and J. S. Lazo. 1989. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice. Mol. Pharmacol. 36:231-238.
21. 21. Donehower, L., and A. Bradley. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155:181-205.
22. 22. Zambetti, G., and A. Levine. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7:855-865.
23. 23. Lee, J., and A. Bernstein. 1995. Apoptosis, cancer and the p53 tumor suppressor gene. Cancer Metastasis Rev. 14:149-161.
24. 24. Vogelstein, B., and K.W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523-526.
25. 25. Harper, J., G. Adami, N. Wei, K. Keyomarsi, and S. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
26. 26. el-Deiry, W., T. Tokino, V. Velculescu, D. Levy, R. Parsons, J. Trent, D. Lin, W. Mercer, K. Kinzler, and B. Vogelstein. 1993. WAF1. a potential mediator of p53 tumor suppression. Cell 75:817-825.
27. 27. Waga, S., G. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 16:520-521.
28. 28. Prelich, G., M. Kostura, D. Marshak, M. Mathews, and B. Stillman. 1987. The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature 326:471-475.
29. 29. Shivji, M., M. Kenny, and R. Wood. 1992. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367-374.
30. 30. Nichols, A., and A. Sancar. 1992. Purification of PCNA as a nucleotide excision repair protein. Nucleic Acids Res. 20:2441-2446.
31. 31. Morris, G., and M. Mathews. 1991. The adenovirus E1A transforming protein activates the proliferating cell nuclear antigen promoter via an activating transcription factor site. J. Virol. 65:6397-6406.
32. 32. Almendral, J., D. Huebsch, P. Blundell, H. Macdonald-Bravo, and R. Bravo. 1987. Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins. Proc. Natl. Acad. Sci. USA 84:1575-1579.
33. 33. Hall, P., P. McKee, H. Menage, R. Dover, and D. Lane. 1993. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8:203-207.
34. 34. Perdue, T., and A. Brody. 1994. Distribution of transforming growth factor-β1, fibronectin and smooth muscle actin in asbestos-induced pulmonary fibrosis in rats. J. Histochem. Cytochem. 42:1061-1070.
35. 35. Martin, W. J. II, and D. L. Kachel. 1989. Oxygen-mediated impairment of human pulmonary endothelial cell growth: evidence for a specific threshold of toxicity. J. Lab. Clin. Med. 113:413-421.
36. 36. Martin, W. J. II, and D. Kachel. 1987. Bleomycin-induced pulmonary endothelial cell injury: protection by the iron chelator deferoxamine, but not EDTA. J. Lab. Clin. Med. 110:153-158.
37. 37. Eitzman, D., R. McCoy, X. Zheng, W. Fay, T. Shen, D. Ginsburg, and R. Simon. 1996. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97:232-237.
38. 38. Mishra, A., J. Y. Liu, A. R. Brody, and G. F. Morris. 1997. Inhaled asbestos fibers induce p53 expression in the rat lung. Am. J. Respir. Cell Mol. Biol. 16:479-485.
39. 39. Hsu, H., I. Raine, and H. Fanger. 1981. A comparative study of the peroxidase-anti-peroxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol. 75:734-738.
40. 40. Sheskin, D. 1997. Handbook of Parametric and Nonparametric Statistical Procedures. CRC Press, New York.
41. 41. Bravo, R., R. Frank, P. Blundell, and H. Macdonald-Bravo. 1987. Cyclin/ PCNA is the auxiliary protein of DNA polymerase-delta. Nature 326:515-517.
42. 42. Murray, A. 1992. Creative blocks: cell-cycle checkpoints and feedback controls. Nature 359:599-604.
43. 43. Kuerbitz, S., B. Plunkett, W. Walsh, and M. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
44. 44. Kastan, M., Q. Zhan, W. El-Deiry, F. Carrier, T. Jacks, W. Walsh, B. Plunkett, B. Vogelstein, and A. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597.
45. 45. Sanchez, Y., and S. Elledge. 1995. Stopped for repairs. Bioessays 17:545-548.
46. 46. Malcomson, R. G. D., M. Oren, A. H. Wyllie, and D. J. Harrison. 1995. p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br. J. Cancer 72:952-957.
47. 47. Antoniades, H., T. Galanopoulos, J. Neville-Golden, C. Kitritsy, and S. Lynch. 1994. p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine. J. Clin. Invest. 93:2206-2214.
48. 48. Xiong, Y., H. Zhang, and D. Beach. 1992. D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505-514.
49. 49. Miyashita, T., and J. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
50. 50. Hagimoto, N., K. Kuwano, Y. Nomoto, R. Kunitake, and N. Hara. 1997. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 16:91-101.
51. 51. Kuwano, K., N. Hagimoto, M. Kawasaki, T. Yatomi, N. Nakamura, S. Nagata. T. Suda, R. Kunitake, T. Maeyama, H. Miyazaki, and N. Hara. 1999. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis [see Comments]. J. Clin. Invest. 104:13-19.
52. 52. Xu, J., and G.F. Morris. 1999. p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. Mol. Cell Biol. 19:12-20.